Discovery of small-sized tris-aryl imidazoles as bifunctional ligands for c-Myc and KRAS G-quadruplexes
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Xue-Zhang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical Schoo…. Hauptthemen laut MEDLINE: G-Quadruplexes, Imidazoles, Antineoplastic Agents, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 33 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program, Shenzhen University, Shenzhen Science and Technology Innovation Committee.
Abstract (Originalsprache)
Tumor growth promotion is achieved by overlapping intrinsic pathways of c-Myc and KRAS, and dual-targeting therapies emerge as an encouraging approach for drug discovery. G-quadruplexes (G4s) exist in the promoter regions of c-Myc and KRAS genes, rendering the transcriptional repression. G4 ligands are widely investigated in recent years, but dual-targeting ligands are still in their early stages. Therefore, tris-aryl imidazole analogs were designed and synthesized, with their binding properties to c-Myc and KRAS G4s confirmed firstly. HZ-1 was proven to be the most promising binder with relative selectivity to parallel G4s than non-parallel G4s. Then, the antitumor efficacy of HZ-1 was verified in human breast cancer MDA-MB-231 cells through NRF2-XCT-GPX4 pathway, resulting in the occurrence of ferroptosis, apoptosis and immunogenic cell death (ICD). Finally, HZ-1 exerted potent tumor growth inhibition in vivo in BALB/c mice, without significant adverse effects to the mice. CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes were promoted by HZ-1 both in spleens and tumors. To sum up, the interaction of HZ analogs with multiple G4s formulates a new concept for anticancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen, 518055, China.
- Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen, 518055, China. Electronic address: wangxiaodong@szu.edu.c…
- Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen, 518055, China. Electronic address: humhao1229@szu.edu.cn.
Förderung
- Shenzhen Science and Technology Innovation Program
- Shenzhen University
- Shenzhen Science and Technology Innovation Committee
Zitieren
APA
Liu, X. Z., Wang, X. D., & Hu, M. H. (2026). Discovery of small-sized tris-aryl imidazoles as bifunctional ligands for c-Myc and KRAS G-quadruplexes. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109656
Vancouver
Liu XZ, Wang XD, Hu MH. Discovery of small-sized tris-aryl imidazoles as bifunctional ligands for c-Myc and KRAS G-quadruplexes. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109656
BibTeX
@article{Liu2026,
author = {Liu, Xue-Zhang and Wang, Xiao-Dong and Hu, Ming-Hao},
title = {Discovery of small-sized tris-aryl imidazoles as bifunctional ligands for c-Myc and KRAS G-quadruplexes},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109656}
}
EUVIMED